血浆蛋白质组学在特发性多中心Castleman病中鉴定出「趋化因子风暴」
本研究对6例特发性多中心Castleman病(iMCD)患者发作期与缓解期的13份血浆样本定量1129种蛋白质,发现趋化因子和补体通路显著富集,CXCL13为上调最显著的细胞因子(log2倍数变化=3.22),提示iMCD涉及「趋化因子风暴」,并观察到TAFRO亚型与NOS亚型间蛋白质组差异。
要点
- iMCD发作期血浆中趋化因子和补体通路显著富集,趋化因子占上调细胞因子比例最大。
- CXCL13在所有患者中上调最显著(log2倍数变化=3.22),淋巴结生发中心CXCL13表达亦显著增加。
- 两例TAFRO患者均对anti-IL-6治疗无应答,四例NOS患者中三例治疗均应答,提示机制差异。
核心结论
- iMCD发作期与缓解期存在蛋白质组差异,趋化因子和补体通路显著富集,提示iMCD涉及「趋化因子风暴」。
- CXCL13是上调最显著的细胞因子,在iMCD淋巴结生发中心也显著增高。
- TAFRO与NOS亚型间蛋白质组谱不同,提示可能存在不同机制,并有望在分子层面定义iMCD亚组。
研究设计与样本
- 对6例iMCD患者发作期和缓解期的13份血浆样本定量1129种蛋白质。
- 比较iMCD淋巴结生发中心与对照的CXCL13表达。
- 比较2例TAFRO患者与4例NOS患者的蛋白质组谱。
主要发现
- 急性期反应物NPS-PLA2是唯一显著升高的蛋白质(P = .017)。
- 趋化因子和补体为显著富集的通路,趋化因子占上调细胞因子比例最大。
- CXCL13在所有患者中上调最显著(log2倍数变化 = 3.22)。
- iMCD淋巴结生发中心CXCL13表达较对照显著增加,呈基质网状模式。
- 2例TAFRO患者均对anti-IL-6治疗无应答,4例NOS患者中3例接受anti-IL-6治疗均应答。
关键数值与推荐
- 发作期与缓解期血浆中NPS-PLA2显著升高(P = .017)。
- CXCL13 log2倍数变化 = 3.22。
- 2例TAFRO患者均anti-IL-6治疗失败,4例NOS患者中3例治疗均应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human Herpesvirus-8 (HHV-8)-negative/idiopathic multicentric Castleman disease (iMCD) is a poorly understood disease involving polyclonal lymphoproliferation with dysmorphic germinal centers, constitutional symptoms, and multi-organ failure. Patients can experience thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly, and normal immunoglobulin levels, - iMCD-TAFRO. Others experience thrombocytosis, milder effusions, and hypergammaglobulinemia, -iMCD-Not Otherwise Specified (iMCD-NOS). Though the etiology is unknown in both subtypes, iMCD symptoms and disease progression are believed to be driven by a cytokine storm, often including interleukin-6 (IL-6). However, approximately two-thirds of patients do not respond to anti-IL-6 therapy; alternative drivers and signaling pathways are not known for anti-IL-6 nonresponders. To identify potential mediators of iMCD pathogenesis, we quantified 1129 proteins in 13 plasma samples from six iMCD patients during flare and remission. The acute phase reactant NPS-PLA2 was the only significantly increased protein (P = .017); chemokines and complement were significantly enriched pathways. Chemokines represented the greatest proportion of upregulated cytokines, suggesting that iMCD involves a chemokine storm. The chemokine CXCL13, which is essential in homing B cells to germinal centers, was the most upregulated cytokine across all patients (log2 fold-change = 3.22). Expression of CXCL13 was also significantly increased in iMCD lymph node germinal centers compared to controls in a stromal meshwork pattern. We observed distinct proteomic profiles between the two iMCD-TAFRO patients, who both failed anti-IL-6-therapy, and the four iMCD-NOS patients, in whom all three treated with anti-IL-6-therapy responded, suggesting that differing mechanisms may exist. This study reveals proteomic differences between flare and remission and the potential to molecularly define iMCD subgroups.
引用
- Pierson SK, Stonestrom AJ, Shilling D, et al. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Am J Hematol. 2018. PMID: 29675946. doi:10.1002/ajh.25123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。